Cancer is one of serious diseases threatening public health. About 12.7 million cases were diagnosed and 7.6 million patients died from cancer in 2008[@b1]. The pathogenesis of cancer remains unknown, but evidence from epidemiological and genetic studies has indicated significant association between inherited and environmental factors and cancer development[@b2][@b3][@b4].

DNA repair systems play critical roles in protecting against mutations and are essential for maintaining the integrity of the genome. Reduced DNA repair capacity (DRC) is reportedly related to an increased risk of cancer[@b5], and single nucleotide polymorphisms (SNPs) located in DNA repair genes may affect gene function and thereby debilitate DRC[@b6].

Flap endonuclease 1 (FEN1) is an evolutionarily conserved component of DNA replication in humans. Based on in vitro results, it processes Okazaki fragments during replication and is involved in base excision repair. FEN1 removes the last primer ribonucleotide on the lagging strand and it cleaves a 5-prime flap that may result from strand displacement during replication or during base excision repair[@b7][@b8][@b9]. In addition, the conserved FEN1 carboxyl terminus binds proliferating cell nuclear antigen and positions FEN1 to act primarily as an exonuclease in DNA replication, in contrast to its endonuclease activity in DNA repair. Therefore, FEN1 play a vital role in maintaining genomic stability and protecting against carcinogenesis.

FEN1 gene is located on the chromosome 11q12.2 region and has some common genetic polymorphisms identified. Among them, -69G\>A (rs174538) and 4150G\>T (rs4246215) polymorphisms have been gaining great attention. Previous studies have suggested that the two polymorphisms in FEN1 may function as biomarkers for cancer risk in Chinese population, including breast cancer, glioma, hepatocellular carcinoma, esophageal cancer, gastric cancer, colorectal cancer, etc[@b10][@b11][@b12][@b13]. However, these studies had relatively small sample sizes, and may lack enough power to assess the associations between *FEN1* -69G\>A and 4150G\>T polymorphisms and cancer risk in Chinese population. Hence, we performed this meta-analysis from all eligible case-control studies to provide a more precise estimation of the associations.

Results
=======

Characteristics of Studies
--------------------------

[Figure 1](#f1){ref-type="fig"} and [Table 1](#t1){ref-type="table"} show the study selection process and main characteristics of included studies, respectively. A total of 9 articles were retrieved based on the search criteria[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18]. Among them, 3 articles were excluded through screening title and abstract[@b14][@b17][@b18]. Then, 2 articles without *FEN1* -69G\>A and 4150G\>T polymorphisms and cancer risk were excluded[@b15][@b16]. Thus, a total of 4 articles with 5,108 cancer cases and 6,382 controls were included in the meta-analysis[@b10][@b11][@b12][@b13]. For the -69G\>A polymorphism, 7 studies were available, including a total of 5,108 cases and 6,381 controls. For the 4150G\>T polymorphism, 7 studies involved a total of 5,071 cases and 6,381 controls. Among them, 4 studies focused on digestive system cancer including hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer, 3 involved with other system cancer, such as breast cancer, glioma and lung cancer. Frequency distribution of the *FEN1* -69G\>A and 4150G\>T haplotypes is shown in [Supplement Table S1](#s1){ref-type="supplementary-material"}. A total of 4 studies with 10,669 cases and 12,761 controls were combined to test the difference in the frequencies of haplotypes. In addition, there are 2 articles involved *FEN1* -69G\>A polymorphism and FEN1 mRNA expression in normal tissues ([Supplement Table S2](#s1){ref-type="supplementary-material"}). In the two articles including five studies, the same assay method (SYBR-Green real-time quantity PCR) and internal reference (β-actin) were used to examine FEN1 mRNA levels. Thus, they were pooled to assess the genotype-mRNA expression correlation.

Quantitative data synthesis
---------------------------

Results of *FEN1* -69G\>A and 4150G\>T polymorphisms and cancer risk are presented in [Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}. For the -69G\>A polymorphism, significant association was observed in all cancer type combined study, including breast cancer, glioma, hepatocellular carcinoma, esophageal cancer, gastric cancer, colorectal cancer and lung cancer (A vs. G: OR = 0.73, 95%CI: 0.69--0.77, *P*~H~ = 0.20; AA vs. GG: OR = 0.54, 95%CI: 0.48--0.61, *P*~H~ = 0.31; AG vs. GG: OR = 0.76, 95%CI: 0.70--0.82, *P*~H~ = 0.39; (AA+AG) vs. GG: OR = 0.70, 95%CI: 0.65--0.75, *P*~H~ = 0.26; AA vs. (AG+GG): OR = 0.62, 95%CI: 0.56--0.69, *P*~H~ = 0.51). Subgroup analysis by cancer type showed that statistically significant associations were also found among digestive system cancer (A vs. G: OR = 0.72, 95%CI: 0.66--0.79, *P*~H~ = 0.99; AA vs. GG: OR = 0.50, 95%CI: 0.41--0.61, *P*~H~ = 0.96; AG vs. GG: OR = 0.80, 95%CI: 0.70--0.91, *P*~H~ = 0.99; (AA+AG) vs. GG: OR = 0.71, 95%CI: 0.63--0.81, *P*~H~ = 1.00; AA vs. (AG+GG): OR = 0.56, 95%CI: 0.47--0.68, *P*~H~ = 0.94).

For the 4150G\>T polymorphism, significant associations with cancer risk were observed in all cancer type combined study (T vs. G: OR = 0.77, 95%CI: 0.73--0.81, *P*~H~ = 0.19; TT vs. GG: OR = 0.59, 95%CI: 0.53--0.67, *P*~H~ = 0.37; TG vs. GG: OR = 0.79, 95%CI: 0.73--0.86, *P*~H~ = 0.16; (TT+TG) vs. GG: OR = 0.74, 95%CI: 0.68--0.79, *P*~H~ = 0.13; TT vs. (TG+GG): OR = 0.67, 95%CI: 0.60--0.75, *P*~H~ = 0.61). In the subgroup analysis by cancer type, statistically significant associations were found in digestive system cancer (T vs. G: OR = 0.76, 95%CI: 0.69--0.83, *P*~H~ = 0.95; TT vs. GG: OR = 0.54, 95%CI: 0.44--0.66, *P*~H~ = 0.98; TG vs. GG: OR = 0.83, 95%CI: 0.73--0.95, *P*~H~ = 0.82; (TT+TG) vs. GG: OR = 0.75, 95%CI: 0.66--0.86, *P*~H~ = 0.87; TT vs. (TG+GG): OR = 0.60, 95%CI: 0.50--0.72, *P*~H~ = 0.98).

In haplotype analysis ([Table 3](#t3){ref-type="table"}), the *FEN1* haplotype (G~-69~G~4150~) comprising the major alleles was taken as reference. The pooled results indicated that G~-69~T~4150~, A~-69~G~4150~ and A~-69~T~4150~ haplotypes were significantly associated with cancer risk (G~-69~T~4150~ vs. G~-69~G~4150~: OR = 0.68, 95%CI: 0.55--0.83, *P*~H~ = 0.00; A~-69~G~4150~ vs. G~-69~G~4150~: OR = 0.41, 95%CI: 0.32--0.51, *P*~H~ = 0.00; A~-69~T~4150~ vs. G~-69~G~4150~: OR = 0.76, 95%CI: 0.70--0.82, *P*~H~ = 0.00).

For *FEN1* -69G\>A polymorphism and FEN1 mRNA expression ([Figure 3](#f3){ref-type="fig"}), the pooled analysis revealed that FEN1 mRNA levels were different between subjects with the -69AA genotype and those with the -69GG and GA genotypes in all included normal tissues (*P* \< 0.001).

Sensitivity analysis
--------------------

The sensitivity analysis indicated that no single study influenced the pooled OR value, either for *FEN1* -69G\>A polymorphism or for *FEN1* 4150G\>T polymorphism, suggesting that the results of this meta-analysis are stable (data not shown).

Publication bias
----------------

Publication bias of the included articles was assessed using Begg\'s funnel plot. As shown in [Figure 4](#f4){ref-type="fig"}, the shape of the funnel plot was symmetrical and did not show an obvious publication bias for *FEN1* -69G\>A or 4150G\>T polymorphism.

Discussion
==========

To the best of our knowledge, this is the first meta-analysis providing comprehensive insights into the effects of *FEN1* -69G\>A and 4150G\>T polymorphisms on the risk of cancer. For the -69G\>A polymorphism in the *FEN1* promoter region, the overall results suggested that the subjects with A allele caused an decreased susceptibility to cancer in Chinese populations. For the 4150G\>T polymorphism in the *FEN1* 3′-untranslated region, results showed that subjects with T allele were associated with the decreased risk of cancer in Chinese populations. However, the previous results showed no associations between the two polymorphisms and the risk of colorectal cancer[@b11]. Considering that the previous single-institution study for colorectal cancer has a small sample size and may not justify the significance of current work, further studies are needed to clarify the effect of the two polymorphisms on the risk of colorectal cancer. In addition, the current results were consistent with the biological function studies. Transient transfection and luciferase assays showed that *FEN1*, a tumor suppressor gene, -69A or 4150T variant has heightened expression in vitro[@b13]. According to cancer type, significantly decreased risks were also observed in digestive system cancer. In addition, similar results were observed in *FEN1* haplotype analysis. Namely, G~-69~T~4150~, A~-69~G~4150~ and A~-69~T~4150~ haplotypes were significantly associated with the decreased risk of cancer in Chinese populations. Interestingly, -69G\>A polymorphism is significantly associated with not only cancer risk but also FEN1 mRNA levels in normal tissues. Subjects with the -69AA genotype had significantly higher FEN1 mRNA levels than those with the -69GG and GA genotypes.

Some limitations should be considered when interpreting our results. Firstly, our results were based on unadjusted estimates, since more accurate outcomes should be adjusted by other confounders including gender, age, body mass index, lifestyle, etc. Secondly, all eligible studies included in this analysis were insufficient, especially in subgroup analysis. Thus, potential publication bias was very likely to exist, in spite of no significant publication bias in our meta-analysis. Thirdly, language of all included studies was limited to English, which may result in potential language bias. Last but not least, the interaction of gene-environment had not been evaluated owing to the absence of original data. However, some advantages should be highlighted in this meta-analysis. The current research could shed lights on the relationship of *FEN1* -69G\>A and 4150G\>T polymorphisms and the decreased susceptibility to cancer in Chinese population, comprehensively and systematically. Additionally, the present research, which had a larger sample size, could enhance the power and persuasion of our conclusion when compared with previous study.

In summary, our meta-analysis suggests that *FEN1* -69G\>A and 4150G\>T polymorphisms and their haplotypes are associated with cancer risk, and *FEN1* -69G\>A polymorphism are associated with FEN1 mRNA expression in normal tissues. However, larger sample sizes of different ethnic populations are required to confirm our findings.

Methods
=======

Search strategy and inclusion criteria
--------------------------------------

We systematically searched literature from PubMed for all relevant studies using the following terms: "flap endonuclease or FNE1" "polymorphism" and "cancer" (up to June 14, 2014). In addition, the references of all retrieved articles were also manually searched for additionally relevant publications. Criteria for eligible studies were as follows: (a) case-control studies, (b) evaluating the association between *FEN1* -69G\>A and/or 4150G\>T polymorphisms and cancer risk in Chinese population, (c) and sufficient information for calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs).

Data extraction
---------------

The re-sampling method was performed as described previously[@b19]. Two authors independently extracted data from eligible studies[@b10][@b11][@b12][@b13]. The following information was collected from each study: first author\'s name, year of publication, country of origin, cancer type, source of control, genotyping methods, the frequency distribution of -69G\>A and 4150G\>T genotypes/alleles/haplotypes. In addition, data of correlations between *FEN1* -69G\>A polymorphism and FEN1 mRNA expression in normal tissues were also extracted from eligible studies[@b11][@b12]. Any disagreements were resolved by discussion with a third investigator.

Statistical Methods
-------------------

All statistical analyses were carried out with the Stata software version 12.0 (Stata Corporation, College Station, TX) and RevMan 5.0 software. Heterogeneity among studies was tested using the Chi square-based Q-test, and *P* value for the heterogeneity test (*P*~H~) \<0.05 was regarded as statistically significant. Based on the heterogeneity test, the pooled OR was calculated using the fixed (*P*~H~ ≥ 0.05) or random (*P*~H~ \< 0.05) effects model. The strength of the associations between *FEN1* -69G\>A and 4150G\>T polymorphisms and their haplotypes and cancer risk was measured by ORs with 95% CIs. The pooled ORs were also estimated for -69G\>A by homozygous (AA vs. GG), heterozygous (AG vs. GG), dominant \[(AA+AG) vs. GG\] and recessive models \[AA vs. (AG+GG)\] as well as allele model (A vs. G) and so was 4150G\>T by homozygous (TT vs. GG), heterozygous (TG vs. GG), dominant \[(TT+TG) vs. GG\] and recessive models \[TT vs. (TG+GG)\] as well as allele model (T vs. G). For *FEN1* -69G\>A and 4150G\>T haplotypes, the pooled ORs were estimated by comparison with G~-69~G~4150~ haplotype (G~-69~T~4150~ vs. G~-69~G~4150~, A~-69~G~4150~ vs. G~-69~G~4150~, A~-69~T~4150~ vs. G~-69~G~4150~). In addition, ORs and 95% CIs were used to assess the associations between *FEN1* -69G\>A polymorphism and FEN1 mRNA expression in normal tissues. Subsequently, in order to ensure that no individual study was entirely responsible for the combined results, sensitivity analysis was performed by omitting each study in turn to assess the quality and consistency of the results. Begg\'s funnel plot was used to evaluate possible publication bias of literatures. All the *P* values \< 0.05 were considered significant.
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###### Main Characteristics of Included Studies in the Meta-Analysis

  First author    Year   Country         Cancer type            Genotyping                                                          Source of control                                                       -69G\>A rs174538   4150G\>T rs4246215                
  -------------- ------ --------- -------------------------- ----------------- --------------------------------------------------------------------------------------------------------------------------- ------------------ -------------------- ------------- -------------
  Lv, Z.          2014    China         Breast cancer            PCR-RFLP                                   Community cancer-screening program for early detection of cancer                                  116/437/547         246/639/515       134/449/517   246/651/503
  Chen, Y. D.     2013    China             Glioma               PCR-RFLP                                                               Hospital                                                               35/122/160         130/356/316       34/120/160    130/363/309
  Liu, L.         2012    China    Hepatocellular carcinoma      PCR-RFLP                                   Community cancer-screening program for early detection of cancer                                   68/290/290         134/334/270       73/295/280    129/335/274
                                      Esophageal cancer                                                                                                                                                        62/249/244         128/331/263       58/255/225    125/336/262
                                        Gastric cancer                                                                                                                                                         41/182/189          76/209/169       42/177/183    76/212/166
                                      Colorectal cancer                                                                                                                                                        28/104/104          54/144/109       27/102/100    52/145/109
  Yang, M.        2009    China          Lung cancer          PCR-RFLP,TaqMan   Community nutritional survey, Community screening program for early detection of cancer and chronic noninfectious disease     253/796/791         354/880/724       271/815/754   358/883/717

###### Results of meta-analysis for *FEN1* -69G\>A and 4150G\>T polymorphisms and cancer risk

  Polymorphism    Type      Allele model      Homozygous model   Heterozygous model   Dominant model    Recessive model                                                             
  -------------- ------- ------------------- ------------------ -------------------- ---------------- ------------------- -------- ------------------- -------- ------------------- --------
  -69G\>A         Total   0.73 (0.69--0.77)         0.20         0.54 (0.48--0.61)         0.31        0.76 (0.70--0.82)    0.39    0.70 (0.65--0.75)    0.26    0.62 (0.56--0.69)    0.51
                   DSC    0.72 (0.66--0.79)         0.99         0.50 (0.41--0.61)         0.96        0.80 (0.70--0.91)    0.99    0.71 (0.63--0.81)    1.00    0.56 (0.47--0.68)    0.94
                  Other   0.72 (0.61--0.84)         0.02         0.56 (0.49--0.65)         0.05        0.74 (0.67--0.82)    0.07    0.67 (0.55--0.81)    0.03    0.65 (0.57--0.75)    0.21
                               T vs. G           TT vs. GG           TG vs. GG        (TT+TG) vs. GG    TT vs. (TG+GG)                                                              
                             OR (95%CI)            *P*~H~            OR (95%CI)           *P*~H~          OR (95%CI)       *P*~H~      OR (95%CI)       *P*~H~      OR (95%CI)       *P*~H~
  4150G\>T        Total   0.77 (0.73--0.81)         0.19         0.59 (0.53--0.67)         0.37        0.79 (0.73--0.86)    0.16    0.74 (0.68--0.79)    0.13    0.67 (0.60--0.75)    0.61
                   DSC    0.76 (0.69--0.83)         0.95         0.54 (0.44--0.66)         0.98        0.83 (0.73--0.95)    0.82    0.75 (0.66--0.86)    0.87    0.60 (0.50--0.72)    0.98
                  Other   0.75 (0.64--0.87)         0.02         0.62 (0.54--0.72)         0.09        0.74 (0.60--0.91)    0.02    0.69 (0.56--0.86)    0.01    0.71 (0.63--0.81)    0.40

Allele model (A vs. G): (AA\*2+GA) vs. (GG\*2+GA); DSC: Digestive system cancer; *P*~H~: *P* value for the heterogeneity test.

###### Results of meta-analysis for *FEN1* haplotypes and cancer risk

                   vs. G~-69~G~4150~  
  --------------- ------------------- ------
  G~-69~T~4150~    0.68 (0.55--0.83)   0.00
  A~-69~G~4150~    0.41 (0.32--0.51)   0.00
  A~-69~T~4150~    0.76 (0.70--0.82)   0.00
